If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> HEMATOLOGY<br /> ISSN 2053-6631 Vol 5.1 • August 2017 • europeanmedical-journal.com<br /> INSIDE<br /> Review of<br /> EHA 2017<br /> Madrid, Spain<br /> CONTENTS<br /> EDITORIAL BOARD...................................................................................................................................... 4<br /> CONGRESS REVIEW.................................................................................................................................... 12<br /> • Review of the 22nd Congress of the European Hematology Association (EHA),<br /> held in Madrid, Spain, 22nd–25th June 2017<br /> INTERVIEWS WITH EMJ HEMATOLOGY EDITORIAL BOARD............................................................ 25<br /> SYMPOSIUM REVIEWS<br /> • SHIFTING TREATMENT PARADIGMS IN NON-HODGKIN LYMPHOMAS..................................... 35<br /> • BIOSIMILARS FOR HAEMATOLOGIC MALIGNANCIES:<br /> <a title="EMJ Hematology 5.1 2017 page 1" href="http://viewer.zmags.com/publication/5e40e0ad?page=1"> HEMATOLOGY ISSN 2053-6631 </a> <a title="EMJ Hematology 5.1 2017 page 2" href="http://viewer.zmags.com/publication/5e40e0ad?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Hematology 5.1 2017 page 3" href="http://viewer.zmags.com/publication/5e40e0ad?page=3"> HEMATOLOGY • THROMBOCYTOPENIA: A DEFECT IN AC</a> <a title="EMJ Hematology 5.1 2017 page 4" href="http://viewer.zmags.com/publication/5e40e0ad?page=4"> EDITORIAL BOARD EDITOR-IN-CHIEF Prof Emili Mont</a> <a title="EMJ Hematology 5.1 2017 page 5" href="http://viewer.zmags.com/publication/5e40e0ad?page=5"> HEMATOLOGY AIMS AND SCOPE • The European </a> <a title="EMJ Hematology 5.1 2017 page 6" href="http://viewer.zmags.com/publication/5e40e0ad?page=6"> HEMATOLOGY 5.1 AUGUST 2017 Director Spencer Gor</a> <a title="EMJ Hematology 5.1 2017 page 7" href="http://viewer.zmags.com/publication/5e40e0ad?page=7"> Welcome A warm welcome to this year’s edition </a> <a title="EMJ Hematology 5.1 2017 page 8" href="http://viewer.zmags.com/publication/5e40e0ad?page=8"> Bosulif (bosutinib): Helping you give the righ</a> <a title="EMJ Hematology 5.1 2017 page 9" href="http://viewer.zmags.com/publication/5e40e0ad?page=9"> Foreword </a> <a title="EMJ Hematology 5.1 2017 page 10" href="http://viewer.zmags.com/publication/5e40e0ad?page=10"> Novartis Pharma AG CH-4002 Basel Switzerland </a> <a title="EMJ Hematology 5.1 2017 page 11" href="http://viewer.zmags.com/publication/5e40e0ad?page=11"> AML is swarming with challenges Strikingly heter</a> <a title="EMJ Hematology 5.1 2017 page 12" href="http://viewer.zmags.com/publication/5e40e0ad?page=12"> </a> <a title="EMJ Hematology 5.1 2017 page 13" href="http://viewer.zmags.com/publication/5e40e0ad?page=13"> EHA ANNUAL CONGRESS 2017 IFEMA - FERIA DE MADRID</a> <a title="EMJ Hematology 5.1 2017 page 14" href="http://viewer.zmags.com/publication/5e40e0ad?page=14"> During the opening ceremony, a 1-day young EHA re</a> <a title="EMJ Hematology 5.1 2017 page 15" href="http://viewer.zmags.com/publication/5e40e0ad?page=15"> Reversible RhoA and Rac Inhibitors: The Key to Pl</a> <a title="EMJ Hematology 5.1 2017 page 16" href="http://viewer.zmags.com/publication/5e40e0ad?page=16"> Future studies will likely be aimed a</a> <a title="EMJ Hematology 5.1 2017 page 17" href="http://viewer.zmags.com/publication/5e40e0ad?page=17"> The results of this trial indicate the next step </a> <a title="EMJ Hematology 5.1 2017 page 18" href="http://viewer.zmags.com/publication/5e40e0ad?page=18"> Diverse T-Lymphocytes are Better at Fighting Leuk</a> <a title="EMJ Hematology 5.1 2017 page 19" href="http://viewer.zmags.com/publication/5e40e0ad?page=19"> The high response rate in this pre-treated, high-</a> <a title="EMJ Hematology 5.1 2017 page 20" href="http://viewer.zmags.com/publication/5e40e0ad?page=20"> ... the inhibitor was generally well-tolerated in</a> <a title="EMJ Hematology 5.1 2017 page 21" href="http://viewer.zmags.com/publication/5e40e0ad?page=21"> Assessment of Early Metabolic Response in Hodgkin</a> <a title="EMJ Hematology 5.1 2017 page 22" href="http://viewer.zmags.com/publication/5e40e0ad?page=22"> ... patients given four cycles of therapy, compar</a> <a title="EMJ Hematology 5.1 2017 page 23" href="http://viewer.zmags.com/publication/5e40e0ad?page=23"> This study has shown that in cancer patients >65 </a> <a title="EMJ Hematology 5.1 2017 page 24" href="http://viewer.zmags.com/publication/5e40e0ad?page=24"> SUBSCRIBE FREE TO OUR YOUTUBE CHANNEL www.youtube</a> <a title="EMJ Hematology 5.1 2017 page 25" href="http://viewer.zmags.com/publication/5e40e0ad?page=25"> Akin Abayomi President, South African Society of</a> <a title="EMJ Hematology 5.1 2017 page 26" href="http://viewer.zmags.com/publication/5e40e0ad?page=26"> poverty and exploitation. In many communities in </a> <a title="EMJ Hematology 5.1 2017 page 27" href="http://viewer.zmags.com/publication/5e40e0ad?page=27"> Q: You are currently working on the biosecurity o</a> <a title="EMJ Hematology 5.1 2017 page 28" href="http://viewer.zmags.com/publication/5e40e0ad?page=28"> In the USA and the European Union (EU), there are</a> <a title="EMJ Hematology 5.1 2017 page 29" href="http://viewer.zmags.com/publication/5e40e0ad?page=29"> to bleed spontaneously or after trauma, whi</a> <a title="EMJ Hematology 5.1 2017 page 30" href="http://viewer.zmags.com/publication/5e40e0ad?page=30"> A: I am confident that next-generation sequencing </a> <a title="EMJ Hematology 5.1 2017 page 31" href="http://viewer.zmags.com/publication/5e40e0ad?page=31"> to the study of haemoglobinopathies, nutritional </a> <a title="EMJ Hematology 5.1 2017 page 32" href="http://viewer.zmags.com/publication/5e40e0ad?page=32"> Society of Hematology and Blood Transfusion </a> <a title="EMJ Hematology 5.1 2017 page 33" href="http://viewer.zmags.com/publication/5e40e0ad?page=33"> patient teaches you something else. Therefor</a> <a title="EMJ Hematology 5.1 2017 page 34" href="http://viewer.zmags.com/publication/5e40e0ad?page=34"> OPEN A NEW DIMENSION OF COMBINATION EFFICACY R</a> <a title="EMJ Hematology 5.1 2017 page 35" href="http://viewer.zmags.com/publication/5e40e0ad?page=35"> SHIFTING TREATMENT PARADIGMS IN NON-HODGKIN LY</a> <a title="EMJ Hematology 5.1 2017 page 36" href="http://viewer.zmags.com/publication/5e40e0ad?page=36"> Follicular Lymphoma: Strategies in the Era of New</a> <a title="EMJ Hematology 5.1 2017 page 37" href="http://viewer.zmags.com/publication/5e40e0ad?page=37"> Impaired T cells • CD4 (T helper cells) recruit o</a> <a title="EMJ Hematology 5.1 2017 page 38" href="http://viewer.zmags.com/publication/5e40e0ad?page=38"> Cell of Origin The World Health Organization </a> <a title="EMJ Hematology 5.1 2017 page 39" href="http://viewer.zmags.com/publication/5e40e0ad?page=39"> is mainly driven by the over-expression of BCL2.3</a> <a title="EMJ Hematology 5.1 2017 page 40" href="http://viewer.zmags.com/publication/5e40e0ad?page=40"> Young patient (≤65 years old)</a> <a title="EMJ Hematology 5.1 2017 page 41" href="http://viewer.zmags.com/publication/5e40e0ad?page=41"> Priming phase </a> <a title="EMJ Hematology 5.1 2017 page 42" href="http://viewer.zmags.com/publication/5e40e0ad?page=42"> The most common, all-grade, immune-related AEs re</a> <a title="EMJ Hematology 5.1 2017 page 43" href="http://viewer.zmags.com/publication/5e40e0ad?page=43"> with CD20-positive B-cell non-Hodgkin lymphoma: a</a> <a title="EMJ Hematology 5.1 2017 page 44" href="http://viewer.zmags.com/publication/5e40e0ad?page=44"> BIOSIMILARS FOR HAEMATOLOGIC MALIGNANCIES: </a> <a title="EMJ Hematology 5.1 2017 page 45" href="http://viewer.zmags.com/publication/5e40e0ad?page=45"> 130 120 110 100 Percentage of SU versus (year</a> <a title="EMJ Hematology 5.1 2017 page 46" href="http://viewer.zmags.com/publication/5e40e0ad?page=46"> back for later stages of disease, and are reserve</a> <a title="EMJ Hematology 5.1 2017 page 47" href="http://viewer.zmags.com/publication/5e40e0ad?page=47"> Sales NME launches Venetoclax, alectinib, cobime</a> <a title="EMJ Hematology 5.1 2017 page 48" href="http://viewer.zmags.com/publication/5e40e0ad?page=48"> medicine trials is to determine the clinical effe</a> <a title="EMJ Hematology 5.1 2017 page 49" href="http://viewer.zmags.com/publication/5e40e0ad?page=49"> 56 46 36 26 Market share (%) 16 6 -4 On</a> <a title="EMJ Hematology 5.1 2017 page 50" href="http://viewer.zmags.com/publication/5e40e0ad?page=50"> from initial use of high-tech chemotherapy and th</a> <a title="EMJ Hematology 5.1 2017 page 51" href="http://viewer.zmags.com/publication/5e40e0ad?page=51"> 15. Gascón P et al. Clinical experience with Zarz</a> <a title="EMJ Hematology 5.1 2017 page 52" href="http://viewer.zmags.com/publication/5e40e0ad?page=52"> Americal Society of Hematology (ASH), 5-8 Decembe</a> <a title="EMJ Hematology 5.1 2017 page 53" href="http://viewer.zmags.com/publication/5e40e0ad?page=53"> PATIENTS IN FOCUS: WHAT’S RELEVANT </a> <a title="EMJ Hematology 5.1 2017 page 54" href="http://viewer.zmags.com/publication/5e40e0ad?page=54"> Welcome and Introduction Professor Michele Bac</a> <a title="EMJ Hematology 5.1 2017 page 55" href="http://viewer.zmags.com/publication/5e40e0ad?page=55"> frequency, leading to further transformation to t</a> <a title="EMJ Hematology 5.1 2017 page 56" href="http://viewer.zmags.com/publication/5e40e0ad?page=56"> Overall, it is important to monitor mutation stat</a> <a title="EMJ Hematology 5.1 2017 page 57" href="http://viewer.zmags.com/publication/5e40e0ad?page=57"> BCR-ABL1 -dependent Drug or patient dependent BCR</a> <a title="EMJ Hematology 5.1 2017 page 58" href="http://viewer.zmags.com/publication/5e40e0ad?page=58"> continues to be effective in maintaining th</a> <a title="EMJ Hematology 5.1 2017 page 59" href="http://viewer.zmags.com/publication/5e40e0ad?page=59"> PONATINIB STEROIDS BCR-ABL FLT3 </a> <a title="EMJ Hematology 5.1 2017 page 60" href="http://viewer.zmags.com/publication/5e40e0ad?page=60"> REFERENCES 1. Baccarani M et al. European Leukem</a> <a title="EMJ Hematology 5.1 2017 page 61" href="http://viewer.zmags.com/publication/5e40e0ad?page=61"> ponatinib as frontline therapy for adults with P</a> <a title="EMJ Hematology 5.1 2017 page 62" href="http://viewer.zmags.com/publication/5e40e0ad?page=62"> Abstract Reviews THE SIMM STUDY: SURVEY OF INTEG</a> <a title="EMJ Hematology 5.1 2017 page 63" href="http://viewer.zmags.com/publication/5e40e0ad?page=63"> EHA 2017 However, the usage patterns and</a> <a title="EMJ Hematology 5.1 2017 page 64" href="http://viewer.zmags.com/publication/5e40e0ad?page=64"> Abstract Reviews Physical Sciences Research Coun</a> <a title="EMJ Hematology 5.1 2017 page 65" href="http://viewer.zmags.com/publication/5e40e0ad?page=65"> EHA 2017 characteristic high surface area-to</a> <a title="EMJ Hematology 5.1 2017 page 66" href="http://viewer.zmags.com/publication/5e40e0ad?page=66"> Abstract Reviews Assessment Programme was con</a> <a title="EMJ Hematology 5.1 2017 page 67" href="http://viewer.zmags.com/publication/5e40e0ad?page=67"> EHA 2017 The initiative was conducted in ni</a> <a title="EMJ Hematology 5.1 2017 page 68" href="http://viewer.zmags.com/publication/5e40e0ad?page=68"> Abstract Reviews central catheters (PICCs) as</a> <a title="EMJ Hematology 5.1 2017 page 69" href="http://viewer.zmags.com/publication/5e40e0ad?page=69"> EHA 2017 In Arm A, 76 open-ended, power-injectab</a> <a title="EMJ Hematology 5.1 2017 page 70" href="http://viewer.zmags.com/publication/5e40e0ad?page=70"> Abstract Reviews those failing primary therapy. </a> <a title="EMJ Hematology 5.1 2017 page 71" href="http://viewer.zmags.com/publication/5e40e0ad?page=71"> EHA 2017 is allogeneic stem cell transplanta</a> <a title="EMJ Hematology 5.1 2017 page 72" href="http://viewer.zmags.com/publication/5e40e0ad?page=72"> EDITOR’S PICK In this comprehensive </a> <a title="EMJ Hematology 5.1 2017 page 73" href="http://viewer.zmags.com/publication/5e40e0ad?page=73"> a poor prognosis.3,4 The mechanisms by which a sm</a> <a title="EMJ Hematology 5.1 2017 page 74" href="http://viewer.zmags.com/publication/5e40e0ad?page=74"> mice.34,35 This lack of an immunophenotypica</a> <a title="EMJ Hematology 5.1 2017 page 75" href="http://viewer.zmags.com/publication/5e40e0ad?page=75"> leukaemia cells within specific niches in the bone</a> <a title="EMJ Hematology 5.1 2017 page 76" href="http://viewer.zmags.com/publication/5e40e0ad?page=76"> These quiescent leukaemia cells localised to the </a> <a title="EMJ Hematology 5.1 2017 page 77" href="http://viewer.zmags.com/publication/5e40e0ad?page=77"> localised to areas of high OPN expression in the </a> <a title="EMJ Hematology 5.1 2017 page 78" href="http://viewer.zmags.com/publication/5e40e0ad?page=78"> 2016;43(11):1213-20. 7. Reya T et al. Stem cells</a> <a title="EMJ Hematology 5.1 2017 page 79" href="http://viewer.zmags.com/publication/5e40e0ad?page=79"> G-CSF in relapsed or refractory acute myeloid leu</a> <a title="EMJ Hematology 5.1 2017 page 80" href="http://viewer.zmags.com/publication/5e40e0ad?page=80"> THROMBOCYTOPENIA: A DEFECT IN ACTIN DYNAMICS? </a> <a title="EMJ Hematology 5.1 2017 page 81" href="http://viewer.zmags.com/publication/5e40e0ad?page=81"> Table 1: Summary of AC-regulating genes associate</a> <a title="EMJ Hematology 5.1 2017 page 82" href="http://viewer.zmags.com/publication/5e40e0ad?page=82"> interacting protein (WIP); loss of WIP by mutatio</a> <a title="EMJ Hematology 5.1 2017 page 83" href="http://viewer.zmags.com/publication/5e40e0ad?page=83"> CONSTITUTIVE DIAPH1 ACTIVATION: DEAFNESS, AUTOSOM</a> <a title="EMJ Hematology 5.1 2017 page 84" href="http://viewer.zmags.com/publication/5e40e0ad?page=84"> α-ACTININ-1 RELATED BLEEDING DISORDER Another pr</a> <a title="EMJ Hematology 5.1 2017 page 85" href="http://viewer.zmags.com/publication/5e40e0ad?page=85"> CONCLUDING REMARKS Numerous factors control t</a> <a title="EMJ Hematology 5.1 2017 page 86" href="http://viewer.zmags.com/publication/5e40e0ad?page=86"> prevent migration of cerebral cortical neuron</a> <a title="EMJ Hematology 5.1 2017 page 87" href="http://viewer.zmags.com/publication/5e40e0ad?page=87"> THE ROLE OF ALLOGRAFT IN ACUTE LYMPHOBLASTIC </a> <a title="EMJ Hematology 5.1 2017 page 88" href="http://viewer.zmags.com/publication/5e40e0ad?page=88"> results with the paediatric protocols in retrospe</a> <a title="EMJ Hematology 5.1 2017 page 89" href="http://viewer.zmags.com/publication/5e40e0ad?page=89"> Table 2: Considerations for allogeneic transplant</a> <a title="EMJ Hematology 5.1 2017 page 90" href="http://viewer.zmags.com/publication/5e40e0ad?page=90"> Table 3: Considerations with allografts for ALL i</a> <a title="EMJ Hematology 5.1 2017 page 91" href="http://viewer.zmags.com/publication/5e40e0ad?page=91"> Also, on a worldwide meta-analysis, sibling donor</a> <a title="EMJ Hematology 5.1 2017 page 92" href="http://viewer.zmags.com/publication/5e40e0ad?page=92"> Other Treatment Options as an Alternative to Allo</a> <a title="EMJ Hematology 5.1 2017 page 93" href="http://viewer.zmags.com/publication/5e40e0ad?page=93"> REFERENCES 1. Leukemia & Lymphoma Society. Facts</a> <a title="EMJ Hematology 5.1 2017 page 94" href="http://viewer.zmags.com/publication/5e40e0ad?page=94"> 38. Goldstone AH et al. In adults with standard-r</a> <a title="EMJ Hematology 5.1 2017 page 95" href="http://viewer.zmags.com/publication/5e40e0ad?page=95"> DOUBLE-HIT AND TRIPLE-HIT LYMPHOMAS: NEW PE</a> <a title="EMJ Hematology 5.1 2017 page 96" href="http://viewer.zmags.com/publication/5e40e0ad?page=96"> in the lymph-nodal structures, is very dyna</a> <a title="EMJ Hematology 5.1 2017 page 97" href="http://viewer.zmags.com/publication/5e40e0ad?page=97"> This lymphoma is considered clinically aggressive</a> <a title="EMJ Hematology 5.1 2017 page 98" href="http://viewer.zmags.com/publication/5e40e0ad?page=98"> In sporadic form and in the form associated with </a> <a title="EMJ Hematology 5.1 2017 page 99" href="http://viewer.zmags.com/publication/5e40e0ad?page=99"> In most cases, there will be a similar appearance</a> <a title="EMJ Hematology 5.1 2017 page 100" href="http://viewer.zmags.com/publication/5e40e0ad?page=100"> A - MYC B - BCL2 C - BCL6 D - MYC E - BCL2 F - BC</a> <a title="EMJ Hematology 5.1 2017 page 101" href="http://viewer.zmags.com/publication/5e40e0ad?page=101"> in the search for selector elements for molecular</a> <a title="EMJ Hematology 5.1 2017 page 102" href="http://viewer.zmags.com/publication/5e40e0ad?page=102"> DLBCL with expression for MYC and/or BCL2 in</a> <a title="EMJ Hematology 5.1 2017 page 103" href="http://viewer.zmags.com/publication/5e40e0ad?page=103"> Swerdlow SH et al., WHO Classification of Tumour</a> <a title="EMJ Hematology 5.1 2017 page 104" href="http://viewer.zmags.com/publication/5e40e0ad?page=104"> MANAGEMENT OF ADULT PATIENTS WITH MYELOD</a> <a title="EMJ Hematology 5.1 2017 page 105" href="http://viewer.zmags.com/publication/5e40e0ad?page=105"> understanding of genetic alterations associat</a> <a title="EMJ Hematology 5.1 2017 page 106" href="http://viewer.zmags.com/publication/5e40e0ad?page=106"> haematological malignancies. Patients wi</a> <a title="EMJ Hematology 5.1 2017 page 107" href="http://viewer.zmags.com/publication/5e40e0ad?page=107"> Besides age, other patient-related factors includ</a> <a title="EMJ Hematology 5.1 2017 page 108" href="http://viewer.zmags.com/publication/5e40e0ad?page=108"> higher bleeding risk in patients treated wi</a> <a title="EMJ Hematology 5.1 2017 page 109" href="http://viewer.zmags.com/publication/5e40e0ad?page=109"> rates in aplastic anaemia, but is not approved fo</a> <a title="EMJ Hematology 5.1 2017 page 110" href="http://viewer.zmags.com/publication/5e40e0ad?page=110"> Intensive chemotherapy Standard AML-based chemo</a> <a title="EMJ Hematology 5.1 2017 page 111" href="http://viewer.zmags.com/publication/5e40e0ad?page=111"> REFERENCES 1. Bonadies N et al.; NICER Wor</a> <a title="EMJ Hematology 5.1 2017 page 112" href="http://viewer.zmags.com/publication/5e40e0ad?page=112"> 41. Casadevall N et al. Health, economic, and qua</a> <a title="EMJ Hematology 5.1 2017 page 113" href="http://viewer.zmags.com/publication/5e40e0ad?page=113"> DIFFERENT THERAPEUTIC INTERVENTIONS AND MECH</a> <a title="EMJ Hematology 5.1 2017 page 114" href="http://viewer.zmags.com/publication/5e40e0ad?page=114"> infection), and anti-malarial prophylaxis (to pre</a> <a title="EMJ Hematology 5.1 2017 page 115" href="http://viewer.zmags.com/publication/5e40e0ad?page=115"> Researchers found that SCD patients </a> <a title="EMJ Hematology 5.1 2017 page 116" href="http://viewer.zmags.com/publication/5e40e0ad?page=116"> Niprisan® (Nix-0699) is a herbal formul</a> <a title="EMJ Hematology 5.1 2017 page 117" href="http://viewer.zmags.com/publication/5e40e0ad?page=117"> GENE THERAPY Developing therapies based on</a> <a title="EMJ Hematology 5.1 2017 page 118" href="http://viewer.zmags.com/publication/5e40e0ad?page=118"> What’s New New Haemophilia Therapy Dramatically</a> <a title="EMJ Hematology 5.1 2017 page 119" href="http://viewer.zmags.com/publication/5e40e0ad?page=119"> Hematology Reversal of Immunotherapy Resistance</a> <a title="EMJ Hematology 5.1 2017 page 120" href="http://viewer.zmags.com/publication/5e40e0ad?page=120"> What’s New Cellular Mechanism of Immune Escape in</a> <a title="EMJ Hematology 5.1 2017 page 121" href="http://viewer.zmags.com/publication/5e40e0ad?page=121"> Hematology Fluorine-labelled Ligand Detects Sites</a> <a title="EMJ Hematology 5.1 2017 page 122" href="http://viewer.zmags.com/publication/5e40e0ad?page=122"> UPCOMING EVENTS 11th Annual Sickle Cell Disease a</a> <a title="EMJ Hematology 5.1 2017 page 123" href="http://viewer.zmags.com/publication/5e40e0ad?page=123"> HEMATOLOGY 12th Dutch Hematology Congress (DHC) 2</a> <a title="EMJ Hematology 5.1 2017 page 124" href="http://viewer.zmags.com/publication/5e40e0ad?page=124"> EUROPEAN MEDICAL JOURNAL provides influential arti</a> <a title="EMJ Hematology 5.1 2017 page 125" href="http://viewer.zmags.com/publication/5e40e0ad?page=125"> Buyer’s Guide • ABBVIE • ADAPTIVE BIOTECHNOL</a> <a title="EMJ Hematology 5.1 2017 page 126" href="http://viewer.zmags.com/publication/5e40e0ad?page=126"> SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS, NEW</a>